Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10908965 | Leukemia Research | 2012 | 5 Pages |
Abstract
Leukemic transformation (LT) of a myeloproliferative neoplasm (MPN) is associated with a dismal prognosis and no medical therapies have shown a survival improvement in patients with MPN in blast phase (MPN-BP). Effective therapies for the treatment of MPN-BP are a serious unmet need. Consensus response criteria do not exist for the treatment of patients with MPN-BP and this is necessary for the uniformed reporting of treatment response in clinical trials. We have identified relevant MPN and MPN-BP features in order to define treatment response categories that reflect hematological, clinical, pathological, cytogenetic and molecular changes after therapeutic intervention. We plan to validate these proposed response criteria within multi-centered clinical trials.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
John Mascarenhas, Mark L. Heaney, Vesna Najfeld, Elizabeth Hexner, Omar Abdel-Wahab, Raajit Rampal, Farhad Ravandi, Bruce Petersen, Gail Roboz, Eric Feldman, Nikolai Podoltsev, Dan Douer, Ross Levine, Martin Tallman, Ronald Hoffman,